Forbes -
18 May 2017 21:57
Earlier this week, THE FDA gave a jolt to Johnson & Johnson's diabetes business when it concluded that J&J must include a label warning that patients using its diabetes drug Invokana are at a higher risk of leg and foot amputation.
Share this Article